{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:26:44Z","timestamp":1793608004071,"version":"4.5.0"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009395","name":"Cancercare Manitoba Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012854","name":"University of Manitoba Children's Hospital Research Institute of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.canlet.2026.218370","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:14:11Z","timestamp":1772151251000},"page":"218370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Harnessing hitchhikers: Outer membrane vesicles leading the way in advanced cancer therapeutics and diagnostic- A review"],"prefix":"10.1016","volume":"647","author":[{"given":"Farzaneh","family":"Sharifzad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sharifzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Thumbikat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helia","family":"Purnaghshband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnaz","family":"Vaseghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Mahmoodzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Assefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek J.","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-508X","authenticated-orcid":false,"given":"Saeid","family":"Ghavami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib1","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218370_bib2","first-page":"139","article-title":"An overview of cancer treatment modalities","volume":"1","author":"Abbas","year":"2018","journal-title":"Neoplasma"},{"key":"10.1016\/j.canlet.2026.218370_bib3","series-title":"Handbook of Oncobiology: from Basic to Clinical Sciences","first-page":"127","article-title":"Advanced therapeutic approaches in cancer therapy","author":"Sobti","year":"2024"},{"key":"10.1016\/j.canlet.2026.218370_bib4","series-title":"Medicinal Plants and Cancer Chemoprevention","first-page":"199","article-title":"Alternative approaches for treatment of cancer","author":"Joshi","year":"2024"},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib5","article-title":"Chemotherapy\u2013types, side effects and resistance","volume":"3","author":"Ismail","year":"2020","journal-title":"Journal of Tomography System and Sensor Application"},{"key":"10.1016\/j.canlet.2026.218370_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-9-214","article-title":"Defining the critical hurdles in cancer immunotherapy","volume":"9","author":"Fox","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218370_bib7","article-title":"The difficulties in cancer treatment","volume":"6","author":"Chakraborty","year":"2012","journal-title":"ecancermedicalscience"},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12032-023-01954-6","article-title":"Chemotherapy: how to reduce its adverse effects while maintaining the potency?","volume":"40","author":"Brianna","year":"2023","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib9","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1038\/s41467-023-38679-z","article-title":"Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy","volume":"14","author":"Ban","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41378-024-00743-z","article-title":"Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy","volume":"10","author":"Gholami","year":"2024","journal-title":"Microsyst. Nanoeng."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/cancers14030627","article-title":"Chemotherapy side-effects: not all DNA damage is equal","volume":"14","author":"van den Boogaard","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218370_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35778","article-title":"Updates on the treatment of epidermal growth factor receptor\u2010mutant non\u2013small cell lung cancer","volume":"131","author":"Kim","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218370_bib13","volume":"vol. II","author":"Su","year":"2023"},{"key":"10.1016\/j.canlet.2026.218370_bib14","first-page":"1","article-title":"Timing and trajectory of BCR:: ABL1-driven chronic myeloid leukaemia","author":"Kamizela","year":"2025","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.canlet.2026.218370_bib15","first-page":"5995","article-title":"Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line","volume":"62","author":"Ricci","year":"2002","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2026.218370_bib16","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218370_bib17","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1054\/bjoc.2001.2127","article-title":"Rituximab: mechanisms and applications British","volume":"85","author":"Glennie","year":"2001","journal-title":"J. Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2026.218370_bib18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3174\/ajnr.A2619","article-title":"Trastuzumab (Herceptin)","volume":"32","author":"G","year":"2011","journal-title":"Am. J. Neuroradiol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218370_bib19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.4078","article-title":"The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death","volume":"22","author":"Pozzi","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ncponc0026","article-title":"Targeting angiogenesis in cancer: clinical development of bevacizumab","volume":"1","author":"Kerr","year":"2004","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218370_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.canlet.2026.218370_bib22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167349","article-title":"Imatinib can act as an allosteric activator of Abl kinase","volume":"434","author":"Xie","year":"2022","journal-title":"J. Mol. Biol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218370_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrc1506","article-title":"Gefitinib\u2014A novel targeted approach to treating cancer","volume":"4","author":"Herbst","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/14737140.3.3.269","article-title":"Erlotinib (Tarceva\u00ae): a promising drug targeting epidermal growth factor receptor tyrosine kinase","volume":"3","author":"Bulgaru","year":"2003","journal-title":"Expet Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1021\/acs.molpharmaceut.2c00792","article-title":"Recent advances in boosting EGFR tyrosine kinase inhibitors-based cancer therapy","volume":"20","author":"Pan","year":"2023","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae(tisagenlecleucel)\u2013an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2026.218370_bib28","series-title":"Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)","article-title":"Treatment and efficacy of Kymriah for three types of blood cancers","author":"Gao","year":"2023"},{"issue":"4","key":"10.1016\/j.canlet.2026.218370_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218370_bib30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2021-151185","article-title":"Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.canlet.2026.218370_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2026.218370_bib32","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218370_bib33","article-title":"Tumor microenvironment: recent advances in various cancer treatments","volume":"22","author":"Wang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"16","key":"10.1016\/j.canlet.2026.218370_bib34","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.canlet.2026.218370_bib35","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12951-024-02664-5","article-title":"A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma","volume":"22","author":"Yueh","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/MEG.0000000000002668","article-title":"Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study","volume":"36","author":"Hua","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218370_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104523","article-title":"Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review","author":"Sprokkerieft","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2026.218370_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2024.101985","article-title":"The prospective role of lapatinib as an adjuvant therapy in prevalent cancers: insights from in silico analysis targeting EGFR and HER2","volume":"78","author":"Dolatabadi","year":"2024","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.canlet.2026.218370_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155607","article-title":"A review on tyrosine kinase inhibitors for targeted breast cancer therapy","author":"Sankarapandian","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib41","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41467-024-44875-2","article-title":"Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial","volume":"15","author":"Cho","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2026.218370_bib42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12032-023-02295-0","article-title":"Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity","volume":"41","author":"You","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218370_bib44","first-page":"1","article-title":"Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial","author":"Gambacorti-Passerini","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2026.218370_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2400985","article-title":"Brigatinib in NF2-Related schwannomatosis with progressive tumors","author":"Plotkin","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218370_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: mechanisms, side effects, and future proteasome inhibitors","volume":"358","author":"Sogbein","year":"2024","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.canlet.2026.218370_bib47","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218370_bib48","article-title":"Mechanism of action of PARP inhibitors","volume":"9","author":"Kim","year":"2024","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218370_bib49","series-title":"Seminars in Cancer Biology","article-title":"Immune checkpoint inhibitors: key trials and an emerging role in breast cancer","author":"Gaynor","year":"2022"},{"issue":"10","key":"10.1016\/j.canlet.2026.218370_bib50","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.bjc.6605499","article-title":"Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours","volume":"102","author":"Gelardi","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib52","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218370_bib53","first-page":"1","article-title":"MET Alterations in Cancer and MET-Targeted Therapy: detection Strategies, Treatment Efficacy, and Emerging Technologies: J. Park et al","author":"Park","year":"2025","journal-title":"Targeted Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib54","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF\u2014A tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218370_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114442","article-title":"The progress of small-molecules and degraders against BCR-ABL for the treatment of CML","volume":"238","author":"Pan","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/cancers13020184","article-title":"Protein tyrosine kinases: their roles and their targeting in leukemia","volume":"13","author":"Bhanumathy","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.canlet.2026.218370_bib57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Cancer"},{"issue":"18","key":"10.1016\/j.canlet.2026.218370_bib59","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-22-3617","article-title":"Acquired secondary HER2 mutations enhance HER2\/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer","volume":"83","author":"Mar\u00edn","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218370_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108344","article-title":"RET aberrant cancers and RET inhibitor therapies: current state-of-the-art and future perspectives","volume":"242","author":"Addeo","year":"2023","journal-title":"Pharmacol. Therapeut."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology","volume":"25","author":"Sabnis","year":"2019","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.canlet.2026.218370_bib62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/antib11010017","article-title":"Immune-and non-immune-mediated adverse effects of monoclonal antibody therapy: a survey of 110 approved antibodies","volume":"11","author":"Baldo","year":"2022","journal-title":"Antibodies"},{"issue":"4","key":"10.1016\/j.canlet.2026.218370_bib66","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis."},{"issue":"5","key":"10.1016\/j.canlet.2026.218370_bib67","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ncponc1087","article-title":"Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy","volume":"5","author":"Loriot","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218370_bib68","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic\u2013immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"509","key":"10.1016\/j.canlet.2026.218370_bib69","doi-asserted-by":"crossref","first-page":"eaaw8412","DOI":"10.1126\/scitranslmed.aaw8412","article-title":"Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials","volume":"11","author":"Lin","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.canlet.2026.218370_bib70","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","article-title":"The expanding role for small molecules in immuno-oncology","volume":"21","author":"Offringa","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218370_bib72","first-page":"E01","article-title":"A comprehensive review on advances in nanoparticle-mediated cancer therapeutics: current research and future perspectives","volume":"2","author":"Deivayanai","year":"2024","journal-title":"Cancer Pathog. Ther."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib73","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-025-02368-w","article-title":"Nanomedicine in cancer therapeutics: current perspectives from bench to bedside","volume":"24","author":"Abdullah","year":"2025","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib74","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jebm.12434","article-title":"ATP\u2010binding cassette (ABC) transporters in cancer: a review of recent updates","volume":"14","author":"Wang","year":"2021","journal-title":"J. Evid. Base Med."},{"key":"10.1016\/j.canlet.2026.218370_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2025.102116","article-title":"Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation","author":"Wusiman","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"9","key":"10.1016\/j.canlet.2026.218370_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202200042","article-title":"The role of hitchhiking in cancer therapeutics\u2014A review","volume":"5","author":"Padmakumar","year":"2022","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.canlet.2026.218370_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.105050","article-title":"Nanocarrier-based drug delivery via cell-hitchhiking: emphasizing pharmacokinetic perspective towards taming the \u201cbig-old\u201d tumors","author":"Famta","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"19","key":"10.1016\/j.canlet.2026.218370_bib78","doi-asserted-by":"crossref","first-page":"eabn1805","DOI":"10.1126\/sciadv.abn1805","article-title":"In vivo hitchhiking of immune cells by intracellular self-assembly of bacteria-mimetic nanomedicine for targeted therapy of melanoma","volume":"8","author":"Gao","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218370_bib79","unstructured":"Zheng, S., X. Li, and S. Guo, Nanomedicine Hitchhiking on Bacteria for Treating Tumors. BMEMat: p. e12110."},{"key":"10.1016\/j.canlet.2026.218370_bib80","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2022.11.034","article-title":"Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics","volume":"353","author":"Famta","year":"2023","journal-title":"J. Contr. Release"},{"issue":"11","key":"10.1016\/j.canlet.2026.218370_bib81","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1007\/s13346-022-01149-y","article-title":"Cell-based carrier for targeted hitchhiking delivery","volume":"12","author":"Liu","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"14","key":"10.1016\/j.canlet.2026.218370_bib82","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.7150\/thno.88002","article-title":"Advanced hitchhiking nanomaterials for biomedical applications","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218370_bib83","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.4c01790","article-title":"Peptide-Hitchhiking for the development of nanosystems in glioblastoma","author":"Branco","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218370_bib84","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.2147\/IJN.S460890","article-title":"Red blood cell-hitchhiking delivery of simvastatin to relieve acute respiratory distress syndrome","author":"Sun","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218370_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.679602","article-title":"Hitchhiking on controlled-release drug delivery systems: opportunities and challenges for cancer vaccines","volume":"12","author":"Han","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218370_bib86","article-title":"In situ cellular hitchhiking of nanoparticles for drug delivery","author":"Udofa","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.canlet.2026.218370_bib87","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1021\/acsnano.9b08693","article-title":"Tumor targeting by \u03b1v\u03b23-integrin-specific lipid nanoparticles occurs via phagocyte hitchhiking","volume":"14","author":"Sofias","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218370_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.679602","article-title":"Hitchhiking on controlled-release drug delivery systems: opportunities and challenges for cancer vaccines","volume":"12","author":"Han","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218370_bib89","series-title":"Development of Albumin-Hitchhiking siRNA Conjugates for Therapeutic Mcl-1 Silencing in Triple Negative Breast Cancer","author":"Hoogenboezem","year":"2022"},{"key":"10.1016\/j.canlet.2026.218370_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119337","article-title":"Advances in siRNA delivery strategies for the treatment of MDR cancer","volume":"274","author":"Subhan","year":"2021","journal-title":"Life Sci."},{"issue":"41","key":"10.1016\/j.canlet.2026.218370_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202003000","article-title":"Retooling cancer nanotherapeutics' entry into tumors to alleviate tumoral hypoxia","volume":"16","author":"Sun","year":"2020","journal-title":"Small"},{"issue":"9","key":"10.1016\/j.canlet.2026.218370_bib92","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/14728222.2023.2259102","article-title":"Exosomes as a drug delivery tool for cancer therapy: a new era for existing drugs and oncolytic viruses","volume":"27","author":"Kakiuchi","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2026.218370_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102102","article-title":"Metal-organic framework nanoparticles hitchhiking on T cells for protein delivery to boost anticancer immunotherapy","volume":"54","author":"Huang","year":"2024","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib94","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-bioeng-121219-024239","article-title":"Red blood cell hitchhiking: a novel approach for vascular delivery of nanocarriers","volume":"23","author":"Brenner","year":"2021","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1061186X.2019.1648479","article-title":"Liposome\u2013ligand conjugates: a review on the current state of art","volume":"28","author":"Ero\u011flu","year":"2020","journal-title":"J. Drug Target."},{"issue":"8","key":"10.1016\/j.canlet.2026.218370_bib96","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/accountsmr.1c00065","article-title":"Incorporation of molecular nanoparticles inside proteins: the trojan horse approach in theranostics","volume":"2","author":"Di Giosia","year":"2021","journal-title":"Acc. Mater. Res."},{"issue":"33","key":"10.1016\/j.canlet.2026.218370_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202302639","article-title":"\u201cTrojan Horse\u201d phototheranostics: fine-engineering NIR\u2010II AIEgen camouflaged by cancer cell membrane for homologous\u2010targeting multimodal imaging\u2010guided phototherapy","volume":"35","author":"Cui","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.canlet.2026.218370_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101503","article-title":"Concise review: cancer cell reprogramming and therapeutic implications","volume":"24","author":"Xiao","year":"2022","journal-title":"Transl. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2026.218370_bib99","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41579-023-00875-5","article-title":"Composition and functions of bacterial membrane vesicles","volume":"21","author":"Toyofuku","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.canlet.2026.218370_bib100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s41048-019-00095-6","article-title":"Natural and engineered bacterial outer membrane vesicles","volume":"5","author":"Qing","year":"2019","journal-title":"Biophysics Reports"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3947\/ic.2022.0145","article-title":"Gram-negative bacteria's outer membrane vesicles","volume":"55","author":"Kim","year":"2023","journal-title":"Infection & Chemotherapy"},{"key":"10.1016\/j.canlet.2026.218370_bib102","article-title":"The role and mechanisms of gram-negative bacterial outer membrane vesicles in inflammatory diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib103","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1490732","article-title":"Outer membrane vesicles (OMVs) produced by gram\u2010negative bacteria: structure, functions, biogenesis, and vaccine application","volume":"2021","author":"Furuyama","year":"2021","journal-title":"BioMed Res. Int."},{"issue":"7","key":"10.1016\/j.canlet.2026.218370_bib104","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00920-19","article-title":"Outer membrane lipid secretion and the innate immune response to gram-negative bacteria","volume":"88","author":"Giordano","year":"2020","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-07288-4","article-title":"Bacterial membrane vesicles transport their DNA cargo into host cells","volume":"7","author":"Bitto","year":"2017","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.canlet.2026.218370_bib106","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1021\/acs.langmuir.3c00378","article-title":"Bacterial outer-membrane-mimicking giant unilamellar vesicle model for detecting antimicrobial permeability","volume":"39","author":"Nandi","year":"2023","journal-title":"Langmuir"},{"key":"10.1016\/j.canlet.2026.218370_bib107","series-title":"Analysis and Optimization of Immune Responses Elicited by Outer Membrane Vesicles (Omvs)","author":"Croia","year":"2023"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13027-023-00480-4","article-title":"Emerging role of microbiota derived outer membrane vesicles to preventive, therapeutic and diagnostic proposes","volume":"18","author":"Jalalifar","year":"2023","journal-title":"Infect. Agents Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib109","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/acsnano.3c05714","article-title":"Surface mineralization of engineered bacterial outer membrane vesicles to enhance tumor photothermal\/immunotherapy","volume":"18","author":"Chen","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218370_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101277","article-title":"Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance","author":"Chai","year":"2025","journal-title":"Drug Resist. Updates"},{"issue":"10","key":"10.1016\/j.canlet.2026.218370_bib111","doi-asserted-by":"crossref","first-page":"8542","DOI":"10.3390\/ijms24108542","article-title":"Outer membrane vesicles (OMVs) as biomedical tools and their relevance as immune-modulating agents against H. pylori infections: current status and future prospects","volume":"24","author":"Ahmed","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112423","article-title":"Antineoplastic activity of Salmonella typhimurium outer membrane nanovesicles","volume":"399","author":"Aly","year":"2021","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib113","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/toxins16030138","article-title":"Heterogeneity of size and toxin distribution in aggregatibacter actinomycetemcomitans outer membrane vesicles","volume":"16","author":"Nice","year":"2024","journal-title":"Toxins"},{"issue":"12","key":"10.1016\/j.canlet.2026.218370_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101049","article-title":"Recent advances in bacterial outer membrane vesicles: effects on the immune system, mechanisms and their usage for tumor treatment","volume":"14","author":"Xiang","year":"2024","journal-title":"J. Pharm. Anal."},{"issue":"11","key":"10.1016\/j.canlet.2026.218370_bib115","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/acsinfecdis.3c00422","article-title":"Heterogeneity and compositional diversities of campylobacter jejuni outer membrane vesicles (OMVs) drive multiple cellular uptake processes","volume":"9","author":"Khan","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.canlet.2026.218370_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106319","article-title":"Helicobacter pylori-derived outer membrane vesicles suppress liver autophagy: a novel mechanism for H. Pylori-mediated hepatic disorder","volume":"183","author":"Shegefti","year":"2023","journal-title":"Microb. Pathog."},{"issue":"19","key":"10.1016\/j.canlet.2026.218370_bib117","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1039\/D2MA00420H","article-title":"Bacterial outer membrane vesicles and their functionalization as vehicles for bioimaging, diagnosis and therapy","volume":"3","author":"Xue","year":"2022","journal-title":"Mater. Adv."},{"key":"10.1016\/j.canlet.2026.218370_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.mib.2025.102695","article-title":"Engineering microbes to modulate innate immune signaling: strategies for host\u2013microbe interactions","volume":"89","author":"Bonanno","year":"2026","journal-title":"Curr. Opin. Microbiol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib119","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7150\/thno.85917","article-title":"Engineered bacterial outer membrane vesicles: a versatile bacteria-based weapon against gastrointestinal tumors","volume":"14","author":"Zheng","year":"2024","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.canlet.2026.218370_bib120","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"13","key":"10.1016\/j.canlet.2026.218370_bib121","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.15252\/embj.201796697","article-title":"Molecular definitions of autophagy and related processes","volume":"36","author":"Galluzzi","year":"2017","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib122","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218370_bib123","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.it.2021.09.006","article-title":"Host immunity and cellular responses to bacterial outer membrane vesicles","volume":"42","author":"Tiku","year":"2021","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218370_bib124","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/toxins15080502","article-title":"Modulation of autophagy and cell death by bacterial outer-membrane vesicles","volume":"15","author":"Pin","year":"2023","journal-title":"Toxins"},{"issue":"4","key":"10.1016\/j.canlet.2026.218370_bib125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1515\/mr-2023-0028","article-title":"Intelligent nanomaterials for cancer therapy: recent progresses and future possibilities","volume":"3","author":"Wang","year":"2023","journal-title":"Medical review"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib126","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41467-023-37369-0","article-title":"Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity","volume":"14","author":"Zhuang","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib127","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41565-023-01553-6","article-title":"Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib128","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","article-title":"Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41467-017-00729-8","article-title":"Bacterial outer membrane vesicles suppress tumor by interferon-\u03b3-mediated antitumor response","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib130","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1038\/s41467-025-60962-4","article-title":"Evaluating cell cycle-and autophagy-associated cellular accumulation of lipid-based nanoparticles","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib131","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12943-024-01934-y","article-title":"Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2026.218370_bib132","doi-asserted-by":"crossref","first-page":"11542","DOI":"10.1002\/cam4.5577","article-title":"Autophagy: a challengeable paradox in cancer treatment","volume":"12","author":"Ahmadi\u2010Dehlaghi","year":"2023","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib133","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41467-024-48032-7","article-title":"Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218370_bib134","series-title":"The LC3-conjugation Machinery Specifies Cargo Loading and Secretion of Extracellular Vesicles","first-page":"1169","author":"Delorme-Axford","year":"2020"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-020-1138-4","article-title":"Autophagy and autophagy-related proteins in cancer","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"7242","key":"10.1016\/j.canlet.2026.218370_bib136","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nature07976","article-title":"Autophagy regulates lipid metabolism","volume":"458","author":"Singh","year":"2009","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.canlet.2026.218370_bib137","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1096\/fj.09-144519","article-title":"Altered lipid content inhibits autophagic vesicular fusion","volume":"24","author":"Koga","year":"2010","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.canlet.2026.218370_bib138","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2353\/ajpath.2006.050959","article-title":"Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents","volume":"168","author":"Li","year":"2006","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib139","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/157489211796957766","article-title":"Lipid rafts and Fas\/CD95 signaling in cancer chemotherapy","volume":"6","author":"Gajate","year":"2011","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12944-025-02563-0","article-title":"Lipid rafts: novel therapeutic targets for metabolic, neurodegenerative, oncological, and cardiovascular diseases","volume":"24","author":"Warda","year":"2025","journal-title":"Lipids Health Dis."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib141","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/ijms26031056","article-title":"Sphingosine-1-Phosphate metabolic pathway in cancer: implications for therapeutic targets","volume":"26","author":"Rufail","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib142","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/s41467-025-56520-7","article-title":"Targeting ceramide transfer protein sensitizes AML to FLT3 inhibitors via a GRP78-ATF6-CHOP axis","volume":"16","author":"Sun","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib143","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218370_bib144","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41419-021-04262-x","article-title":"Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells","volume":"12","author":"Schroeder","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13046-022-02567-z","article-title":"Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis","volume":"42","author":"Li","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218370_bib146","first-page":"1","article-title":"Structural dynamics of human fatty acid synthase in the condensing cycle","author":"Choi","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218370_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101846","article-title":"Inhibiting the endoplasmic reticulum stress response enhances the effect of doxorubicin by altering the lipid metabolism of liver cancer cells","volume":"79","author":"Kopsida","year":"2024","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.canlet.2026.218370_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601266","article-title":"Cancer cell-derived extracellular vesicles: a potential target for overcoming tumor immunotherapy resistance and immune evasion strategies","volume":"16","author":"Ahn","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218370_bib149","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1007\/s12035-017-0582-7","article-title":"Exosomes and their application in biomedical field: difficulties and advantages","volume":"55","author":"Rezaie","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib150","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00634-21","article-title":"Lipidomics analysis of outer membrane vesicles and elucidation of the inositol phosphoceramide biosynthetic pathway in Bacteroides thetaiotaomicron","volume":"10","author":"Sartorio","year":"2022","journal-title":"Microbiol. Spectr."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib151","doi-asserted-by":"crossref","DOI":"10.1042\/EBC20253004","article-title":"Potential of bacterial outer membrane vesicles in tumor vaccine: characteristics, advancements, and future directions","volume":"69","author":"Yang","year":"2025","journal-title":"Essays Biochem."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/mba2.70013","article-title":"Bacterial outer membrane vesicles: from physics to clinical","volume":"4","author":"Zhou","year":"2025","journal-title":"MedComm\u2013Biomaterials and Applications"},{"issue":"8","key":"10.1016\/j.canlet.2026.218370_bib153","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.apsb.2020.02.002","article-title":"Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung cancer","volume":"10","author":"Kuerban","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218370_bib154","article-title":"Effects of biofilm nano-composite drugs OMVs-MSN-5-FU on cervical lymph node metastases from oral squamous cell carcinoma","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218370_bib155","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1021\/nn405724x","article-title":"Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy","volume":"8","author":"Gujrati","year":"2014","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.canlet.2026.218370_bib156","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12357","article-title":"Mass\u2010produced gram\u2010negative bacterial outer membrane vesicles activate cancer antigen\u2010specific stem\u2010like CD8+ T cells which enables an effective combination immunotherapy with anti\u2010PD\u20101","volume":"12","author":"Won","year":"2023","journal-title":"J. Extracell. Vesicles"},{"issue":"12","key":"10.1016\/j.canlet.2026.218370_bib157","doi-asserted-by":"crossref","first-page":"16698","DOI":"10.1021\/acsnano.0c03776","article-title":"Bacterial outer membrane vesicles presenting programmed death 1 for improved cancer immunotherapy via immune activation and checkpoint inhibition","volume":"14","author":"Li","year":"2020","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.canlet.2026.218370_bib158","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12120","article-title":"Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy","volume":"10","author":"Park","year":"2021","journal-title":"J. Extracell. Vesicles"},{"issue":"7","key":"10.1016\/j.canlet.2026.218370_bib159","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/nano11071661","article-title":"Combining augmented radiotherapy and immunotherapy through a nano-gold and bacterial outer-membrane vesicle complex for the treatment of glioblastoma","volume":"11","author":"Chen","year":"2021","journal-title":"Nanomaterials"},{"issue":"27","key":"10.1016\/j.canlet.2026.218370_bib160","doi-asserted-by":"crossref","first-page":"eaba2735","DOI":"10.1126\/sciadv.aba2735","article-title":"Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL\u2013programmed therapy against melanoma","volume":"6","author":"Peng","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib161","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s40001-024-01937-x","article-title":"Therapeutic potential of extracellular vesicles from diverse sources in cancer treatment","volume":"29","author":"Lin","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.canlet.2026.218370_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114321","article-title":"Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy","volume":"186","author":"Long","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib163","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2020043","article-title":"Product review on the IMD serogroup B vaccine Bexsero\u00ae","volume":"18","author":"Deghmane","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"issue":"20","key":"10.1016\/j.canlet.2026.218370_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202109984","article-title":"Rapid surface display of mRNA antigens by bacteria\u2010derived outer membrane vesicles for a personalized tumor vaccine","volume":"34","author":"Li","year":"2022","journal-title":"Adv. Mater."},{"issue":"7","key":"10.1016\/j.canlet.2026.218370_bib165","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1073\/pnas.0805532107","article-title":"Delivery of foreign antigens by engineered outer membrane vesicle vaccines","volume":"107","author":"Chen","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218370_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.actbio.2025.05.028","article-title":"Bacterial extracellular vesicles: bridging pathogen biology and therapeutic innovation","author":"Moghaddam","year":"2025","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib167","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1038\/s41598-024-55734-x","article-title":"Structural basis for the recognition of human hemoglobin by the heme-acquisition protein Shr from Streptococcus pyogenes","volume":"14","author":"Senoo","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218370_bib168","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fcimb.2019.00081","article-title":"Heme uptake and utilization by gram-negative bacterial pathogens","volume":"9","author":"Richard","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218370_bib169","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.biotechadv.2017.05.003","article-title":"Bioengineering bacterial outer membrane vesicles as vaccine platform","volume":"35","author":"Gerritzen","year":"2017","journal-title":"Biotechnol. Adv."},{"issue":"7","key":"10.1016\/j.canlet.2026.218370_bib170","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1007\/s12094-023-03115-7","article-title":"Mesenchymal stem cells-derived secretome and extracellular vesicles: perspective and challenges in cancer therapy and clinical applications","volume":"25","author":"Gemayel","year":"2023","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib171","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.canlet.2026.218370_bib172","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","article-title":"The roles of extracellular vesicles in the immune system","volume":"23","author":"Buzas","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218370_bib173","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1021\/acs.jafc.3c06867","article-title":"Plant-derived extracellular vesicles: a new revolutionization of modern healthy diets and biomedical applications","volume":"72","author":"Lo","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.canlet.2026.218370_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1215650","article-title":"Plant and mammalian-derived extracellular vesicles: a new therapeutic approach for the future","volume":"11","author":"Sall","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218370_bib175","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.3390\/molecules27123941","article-title":"Theragnostic applications of mammal and plant-derived extracellular vesicles: latest findings, current technologies, and prospects","volume":"27","author":"Ali","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2026.218370_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155750","article-title":"Plant-derived extracellular vesicles as a promising anti-tumor approach: a comprehensive assessment of effectiveness, safety, and mechanisms","volume":"130","author":"Qiang","year":"2024","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib177","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12964-022-00889-1","article-title":"Plant-derived extracellular vesicles: a novel nanomedicine approach with advantages and challenges","volume":"20","author":"Nemati","year":"2022","journal-title":"Cell Commun. Signal."},{"issue":"12","key":"10.1016\/j.canlet.2026.218370_bib178","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3390\/pr12122938","article-title":"Plant-derived extracellular vesicles: natural nanocarriers for biotechnological drugs","volume":"12","author":"Calzoni","year":"2024","journal-title":"Processes"},{"key":"10.1016\/j.canlet.2026.218370_bib179","article-title":"Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218370_bib180","doi-asserted-by":"crossref","DOI":"10.1021\/acs.nanolett.5c04371","article-title":"Bacterial membrane coating potentiates lipid nanoparticles for mRNA delivery","author":"Wang","year":"2025","journal-title":"Nano Lett."},{"key":"10.1016\/j.canlet.2026.218370_bib181","series-title":"Bacterial Extracellular Vesicles: Methods and Protocols","first-page":"219","article-title":"Dose determination and administration of bacterial extracellular vesicles for in vivo preclinical studies","author":"Lathia","year":"2024"},{"issue":"5","key":"10.1016\/j.canlet.2026.218370_bib182","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12447","article-title":"Lipid A in outer membrane vesicles shields bacteria from polymyxins","volume":"13","author":"Burt","year":"2024","journal-title":"J. Extracell. Vesicles"},{"issue":"9","key":"10.1016\/j.canlet.2026.218370_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.70150","article-title":"Outer membrane vesicles as a versatile platform for vaccine development: engineering strategies, applications and challenges","volume":"14","author":"Garling","year":"2025","journal-title":"J. Extracell. Vesicles"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-024-02935-1","article-title":"Opportunities and challenges of bacterial extracellular vesicles in regenerative medicine","volume":"23","author":"Guo","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"33","key":"10.1016\/j.canlet.2026.218370_bib185","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400049","article-title":"Engineering versatile bacteria\u2010derived outer membrane vesicles: an adaptable platform for advancing cancer immunotherapy","volume":"11","author":"Luo","year":"2024","journal-title":"Adv. Sci."},{"issue":"41","key":"10.1016\/j.canlet.2026.218370_bib186","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1002\/smll.201501284","article-title":"Nanoparticle\u2010based manipulation of antigen\u2010presenting cells for cancer immunotherapy","volume":"11","author":"Fang","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.canlet.2026.218370_bib187","first-page":"65","article-title":"Chapter-5 genetically modified organisms: applications and related ethical issues","author":"Mehra","year":"2020","journal-title":"Biotechnology Bioscience"},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib188","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.3892\/mmr.2017.6983","article-title":"LPS enhances TLR4 expression and IFN-\u03b3 production via the TLR4\/IRAK\/NF-\u03baB signaling pathway in rat pulmonary arterial smooth muscle cells","volume":"16","author":"Wang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2026.218370_bib189","author":"Verma","year":"2025","journal-title":"Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future Directions"},{"key":"10.1016\/j.canlet.2026.218370_bib190","article-title":"Investigation of potential toxic effects of engineered nanoparticles and biologic microparticles in blood and their biomarker applications","author":"Simak","year":"2022","journal-title":"US Foo Dru Admin"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib191","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamainternmed.2020.3997","article-title":"Assessment of availability, clinical testing, and US food and drug administration review of biosimilar biologic products","volume":"181","author":"Moore","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.canlet.2026.218370_bib192","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib193","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.canlet.2026.218370_bib194","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3390\/pharmaceutics12121156","article-title":"Recent advances and challenges in controlling the spatiotemporal release of combinatorial anticancer drugs from nanoparticles","volume":"12","author":"Yoon","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.canlet.2026.218370_bib195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12964-022-00959-4","article-title":"A review on exosomes application in clinical trials: perspective, questions, and challenges","volume":"20","author":"Rezaie","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2026.218370_bib196","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1541636","article-title":"Outer membrane vesicles in gram-negative bacteria and its correlation with pathogenesis","volume":"16","author":"Abolhasani","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218370_bib197","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1177440","article-title":"Inhibition of autophagy; an opportunity for the treatment of cancer resistance","volume":"11","author":"Tonkin-Reeves","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218370_bib198","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1080\/15548627.2024.2356486","article-title":"Gonococcal OMVs induce epithelial cell mitophagy in a dual PorB-dependent manner to enhance intracellular survival","volume":"20","author":"Gao","year":"2024","journal-title":"Autophagy"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:35:34Z","timestamp":1793604934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526001333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":198,"alternative-id":["S0304383526001333"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218370","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing hitchhikers: Outer membrane vesicles leading the way in advanced cancer therapeutics and diagnostic- A review","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218370"}}